CRISPR therapy corrects muscular dystrophy mutations and regrows muscles in mice

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and Charité—Universitätsmedizin Berlin, have developed a promising gene-editing approach intended to restore the function of a protein that is essential to repair and regrow muscle in patients with muscular dystrophy diseases. The findings are published in the journal Nature Communications.